ArQule Message Board - Msg: 10786445

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ArQule

ARQL 20.00

0.0%

Jan 16 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tommysdad who wrote (371)	8/2/1999 8:11:00 PM
From: Herc	Read Replies (4) of 399

'Splain it to me. SEPR goes in and slightly alters a known drugs molecule so that it will have less side effects and can be patented for however many years are allowed for a new drug? But can't the generic drug companies undercut their price with the old compound now off patent? It's not like SEPR is creating whole new classes of drugs. I'm an ophthalmologist and can tell you that most people don't suffer side effects from drugs. Otherwise the drug would have never been released in the first place if the hazards outweighed the benefits. Keeping the ARQL thread alive... Herc

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next